ClinicalTrials.gg
CompletedNCT01432535Updated Apr 7, 2017Results posted

Pharmacokinetics of Peginterferon Alfa-2b in Participants With Moderate and Severe Renal Impairment (P05655)

A Phase 1 interventional study of PegIFN-2b (Sylatron®) in Renal Insufficiency, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-04-07.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Non-randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies in Renal Insufficiency by Merck & Co., Inc — 2 open to participants now, 2 under way, none of them phase 3. Renal Insufficiency · Merck & Co., Inc.

Enrollment
17th of 32
25 · median 26
Started
2011
with 1 other
Phase 1
25 of 32
2 open now
Registered
10th of 32
by date

Among the 32 studies in Renal Insufficiency by Merck & Co., Inc, this one is the 17th largest by enrollment, is one of 2 that started in 2011, is one of 25 in phase 1, and was the 10th registered.

Renal Insufficiency

1,412 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

2 of the 32 studies in Renal Insufficiency by Merck & Co., Inc are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Renal Insufficiency by Merck & Co., Inc, or all of them as a file.
02

Study summary

This study will compare the pharmacokinetics of a single dose of peginterferon alfa-2b (Sylatron®) in healthy participants to that in participants with moderate to severe impairment of kidney function.

03

Conditions studied

  • Renal Insufficiency

Browse trials for

04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) between 19 to 40 kg/m\^2, inclusive
  • Moderate renal impairment and severe renal impairment and/or end-stage renal disease (ESRD) who may require hemodialysis and normal renal function
  • Free of any disease (except those related to renal disease and comorbid conditions) that requires a physician's care and would interfere with the study
  • Females of must have used a medically accepted method of for three months prior to screening and must agree to use an accepted contraceptive method during and for two months following the study
  • Males must agree to use a medically accepted method of contraception during the trial and for 3 months after the study

Exclusion criteria

Exclusion Criteria:

  • Pregnant, intend to become pregnant, or breastfeeding
  • Surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of any drug
  • History of any infectious disease within 4 weeks prior to study drug administration that affects ability to participate in the study
  • Positive for surface antigen, and/or for (HIV) antibodies. Healthy participants positive for antibodies
  • Previously received PegIntron®, Sylatron®, and/or Pegasys
  • More than 10 cigarettes or equivalent tobacco use per day
  • History of
  • Hypothyroidism or hyperthyroidism
  • History of depression requiring treatment with psychotherapy or medication
  • History of suicidality or at risk of self-harm or harm to others
  • History of disorder requiring medical therapy
  • Immune mediated renal insufficiency
  • Removal of a kidney (healthy participants) or functioning renal transplant (participants with renal impairment)
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Active comparator
    Healthy Participants

    Participants with normal renal function defined as having a creatinine clearance test value of ≥80 mL/min/1.73 m\^2. Participants receive a single subcutaneous dose of PegIFN-2b, 4.5 μg/kg.

    Drug: PegIFN-2b (Sylatron®)

  • Experimental
    Participants with Moderate Renal Impairment

    Participants with moderate renal impairment defined as having a creatinine clearance test value of 30-50 mL/min/1.73 m\^2. Participants receive a single subcutaneous dose of PegIFN-2b, 4.5 μg/kg.

    Drug: PegIFN-2b (Sylatron®)

  • Experimental
    Participants with Severe Renal Impairment

    Participants with severe renal impairment defined as having a creatinine clearance test value of \<30 mL/min/1.73 m\^2 or end stage renal disease on hemodialysis. Participants receive a single subcutaneous dose of PegIFN-2b, 4.5 μg/kg.

    Drug: PegIFN-2b (Sylatron®)

Interventions

  • Single 4.5 μg/kg dose

    Also known as: PegIntron®, Peginterferon alfa-2b, SCH 054031, MK-4031

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-time Curve From Time 0 to Infinity (AUC0-∞)

    AUC0-∞ is a measure of the mean concentration levels of drug in the plasma after the dose.

    Time frame: From hour 0 (pre-dose) to 288 hours post-dose

  2. AUC From Time 0 to the Last Measurable Sample (AUC0-last)

    AUC0-last is a measure of the total amount of drug in the plasma from the dose to the last measurable sample.

    Time frame: From hour 0 (pre-dose) up to 288 hours post-dose

  3. Maximum Observed Serum Concentration (Cmax)

    Cmax is a measure of the maximum amount of drug in the plasma after the dose is given.

    Time frame: From hour 0 (pre-dose) to 288 hours post-dose

  4. Time to Maximum Observed Serum Concentration (Tmax)

    Tmax is a measure of the time to reach the maximum concentration in the plasma after the drug dose.

    Time frame: From hour 0 (pre-dose) up to 288 hours post-dose

  5. Apparent Terminal Half-life (T1/2)

    T1/2 is the time required for a given drug concentration in the plasma to decrease by 50%.

    Time frame: From hour 0 (pre-dose) up to 288 hours post-dose

  6. Apparent Total Body Clearance (CL/F)

    CL/F is a calculation of the rate at which a drug is removed from the body via renal, hepatic and other clearance pathways, expressed as volume (milliliters) per unit of time (minutes).

    Time frame: From hour 0 (pre-dose) up to 288 hours post-dose

  7. Apparent Volume of Distribution (Vd/F)

    Vd/F is defined as the distribution of a medication between the plasma and the rest of the body after the dose. It is the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of the drug.

    Time frame: From hour 0 (pre-dose) up to 288 hours post-dose

07

Results

Posted Sep 25, 2013

Participant flow

Participant flow — Overall Study
MilestoneHealthy ParticipantsParticipants With Moderate Renal ImpairmentParticipants With Severe Renal Impairment
Started1276
Completed1276
Not completed000

Outcome measures

PrimaryArea Under the Concentration-time Curve From Time 0 to Infinity (AUC0-∞)

AUC0-∞ is a measure of the mean concentration levels of drug in the plasma after the dose.

Time frame:
From hour 0 (pre-dose) to 288 hours post-dose
Reported as:
Least squares mean · pg*hr/mL
Area Under the Concentration-time Curve From Time 0 to Infinity (AUC0-∞)
pg*hr/mLHealthy ParticipantsParticipants With Moderate Renal ImpairmentParticipants With Severe Renal Impairment
Area Under the Concentration-time Curve From Time 0 to Infinity (AUC0-∞)305315.22 (175840.19 to 530125.58)435500.38 (248562.28 to 763030.40)658413.69 (395164.74 to 10907032.58)
PrimaryAUC From Time 0 to the Last Measurable Sample (AUC0-last)

AUC0-last is a measure of the total amount of drug in the plasma from the dose to the last measurable sample.

Time frame:
From hour 0 (pre-dose) up to 288 hours post-dose
Reported as:
Least squares mean · pg*hr/mL
AUC From Time 0 to the Last Measurable Sample (AUC0-last)
pg*hr/mLHealthy ParticipantsParticipants With Moderate Renal ImpairmentParticipants With Severe Renal Impairment
AUC From Time 0 to the Last Measurable Sample (AUC0-last)286946.43 (164687.09 to 499967.87)408889.84 (232550.52 to 718944.43)598863.88 (358269.15 to 1001029.37)
PrimaryMaximum Observed Serum Concentration (Cmax)

Cmax is a measure of the maximum amount of drug in the plasma after the dose is given.

Time frame:
From hour 0 (pre-dose) to 288 hours post-dose
Reported as:
Geometric mean · pg/mL
Maximum Observed Serum Concentration (Cmax)
pg/mLHealthy ParticipantsParticipants With Moderate Renal ImpairmentParticipants With Severe Renal Impairment
Maximum Observed Serum Concentration (Cmax)2547.85 (1115.61 to 5818.84)3210.16 (1386.73 to 7431.24)3551.03 (1653.85 to 7624.49)
PrimaryTime to Maximum Observed Serum Concentration (Tmax)

Tmax is a measure of the time to reach the maximum concentration in the plasma after the drug dose.

Time frame:
From hour 0 (pre-dose) up to 288 hours post-dose
Reported as:
Median · hours
Time to Maximum Observed Serum Concentration (Tmax)
hoursHealthy ParticipantsParticipants With Moderate Renal ImpairmentParticipants With Severe Renal Impairment
Time to Maximum Observed Serum Concentration (Tmax)12.0 (9.0 to 72.0)12.0 (12.0 to 72.0)60.0 (24.0 to 96.3)
PrimaryApparent Terminal Half-life (T1/2)

T1/2 is the time required for a given drug concentration in the plasma to decrease by 50%.

Time frame:
From hour 0 (pre-dose) up to 288 hours post-dose
Reported as:
Geometric mean · Hours
Apparent Terminal Half-life (T1/2)
HoursHealthy ParticipantsParticipants With Moderate Renal ImpairmentParticipants With Severe Renal Impairment
Apparent Terminal Half-life (T1/2)41.9 ± 31.950.7 ± 12.758.1 ± 17.2
PrimaryApparent Total Body Clearance (CL/F)

CL/F is a calculation of the rate at which a drug is removed from the body via renal, hepatic and other clearance pathways, expressed as volume (milliliters) per unit of time (minutes).

Time frame:
From hour 0 (pre-dose) up to 288 hours post-dose
Reported as:
Number · mL/min
Apparent Total Body Clearance (CL/F)
mL/minHealthy ParticipantsParticipants With Moderate Renal ImpairmentParticipants With Severe Renal Impairment
Apparent Total Body Clearance (CL/F)18.5 (10.42 to 32.85)12.72 (7.10 to 22.81)8.02 (4.71 to 13.64)
PrimaryApparent Volume of Distribution (Vd/F)

Vd/F is defined as the distribution of a medication between the plasma and the rest of the body after the dose. It is the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of the drug.

Time frame:
From hour 0 (pre-dose) up to 288 hours post-dose
Reported as:
Geometric mean · Liters
Apparent Volume of Distribution (Vd/F)
LitersHealthy ParticipantsParticipants With Moderate Renal ImpairmentParticipants With Severe Renal Impairment
Apparent Volume of Distribution (Vd/F)90.63 (41.76 to 196.69)72.26 (32.88 to 158.82)55.90 (27.30 to 114.49)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Healthy Participants—0/12 (0%)12/12 (100%)
Participants With Moderate Renal Impairment—0/7 (0%)7/7 (100%)
Participants With Severe Renal Impairment—1/6 (16.7%)6/6 (100%)
Most frequent serious events
Most frequent serious events
EventHealthy ParticipantsParticipants With Moderate Renal ImpairmentParticipants With Severe Renal Impairment
HypoglycaemiaMetabolism and nutrition disorders0/120/71/6
Most frequent other events
Showing 10 of 30
Most frequent other events
EventHealthy ParticipantsParticipants With Moderate Renal ImpairmentParticipants With Severe Renal Impairment
PyrexiaGeneral disorders9/126/74/6
ChillsGeneral disorders9/125/73/6
HeadacheNervous system disorders8/124/73/6
NauseaGastrointestinal disorders2/122/73/6
Decreased appetiteMetabolism and nutrition disorders2/123/71/6
MalaiseGeneral disorders4/121/70/6
VomitingGastrointestinal disorders3/122/71/6
FatigueGeneral disorders0/122/70/6
DizzinessNervous system disorders0/122/71/6
MyalgiaMusculoskeletal and connective tissue disorders3/121/70/6

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Healthy ParticipantsParticipants With Moderate Renal ImpairmentParticipants With Severe Renal ImpairmentTotal
Mean57.33 ± 9.6364.00 ± 6.2352.67 ± 12.7457.83 ± 10.25
Sex: Female, Male
Sex: Female, Male(Participants)Healthy ParticipantsParticipants With Moderate Renal ImpairmentParticipants With Severe Renal ImpairmentTotal
Female1012
Male116522
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Aug 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2013, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2011
First posted
Sep 13, 2011
Start
Nov 2011
Primary completionActual
Aug 2012
CompletionActual
Aug 2012
Results first posted
Sep 25, 2013
Last update
Apr 7, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01432535
Responsible party
Sponsor
First posted
Sep 13, 2011
Start date
Nov 2011
Primary completion
Aug 2012
Completion
Aug 2012
Results posted
Sep 25, 2013
Last update
Apr 7, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Peginterferon alfa-2b

Start the discussion